恩替卡韦联合康莱特注射液治疗乙型肝炎患者晚期肝癌的临床观察  

Clinical observation of entecavir and kanglaite injection combined treatment to hepatitis b patients with advanced hepatocarcinoma

作　　者：江明万[1] 王晴雷[1] 于双[1] 李亮[1] 陈平[1] 

机构地区：[1]重庆三峡中心医院消化科,重庆404100

出　　处：《中华医院感染学杂志》2016年第16期3628-3630,共3页Chinese Journal of Nosocomiology

基　　金：重庆市科技局基金资助项目(2012-2-6-1)

摘　　要：目的分析恩替卡韦联合康莱特注射液治疗乙型肝炎患者晚期肝癌的临床效果,为临床治疗提供科学依据。方法选取2012年11月-2014年11月医院收治76例乙型肝炎病毒感染晚期肝癌患者为研究对象,根据不同的治疗方法分为对照和试验两组,各38例;对照组患者采取常规治疗方法加康莱特注射液进行治疗,试验组在对照组的基础上加用恩替卡韦联合治疗,观察两组患者的临床指标及稳定率,数据采用SPSS 18.0软件进行统计分析。结果两组患者在接受治疗前ALT、AST、TBIL、ALB 4个指标比较,差异无统计学意义;接受治疗后,试验组ALT、AST、TBIL降低幅度以及ALB升高幅度均明显高于对照组,差异有统计学意义(P<0.05);试验组总稳定率为92.11%,高于对照组的63.16%,差异有统计学意义(P<0.05)。结论采用恩替卡韦康莱特注射液联合治疗乙型肝炎病毒感染晚期肝癌疗效明显,值得临床推广。OBJECTIVE To analyze the clinical effect of entecavir and kanglaite injection combined treatment to patients with advanced hepatocarcinoma and chronic hepatitis B,so as to provide scientific basis for clinical treatment.METHODS A total of 76 cases of hepatitis B virus infection in patients with advanced hepatocarcinoma treated in hospital were selected for the study in Nov.2012-Nov.2014,and were divided into two groups according to different treatment methods,each group with 38 cases.In control group,patients took conventional treatments combined with kanglaite injection,on the basis of treatments to control group,the test group using entecavir combination therapy.Clinical indexes and stability rate were under observation in two groups and SPSS 18.0was used for statistic analysis.RESULTS The four indexes ALT,AST,TBIL,and ALB in two groups had no significant difference before the treatment;ALT,AST and TBIL in test group decreased more significantly than those in control group and ALB increased more significantly than that in control group（P〈0.05）.The stability rate in test group was 92.11%,totally higher than 63.16%in control group,which had significant difference（P〈0.05）.CONCLUSION The clinical effect of entecavir and kanglaite injection combined treatment to patients with advanced hepatocarcinoma and chronic hepatitis B is obvious,and it is worthy for clinical promotion.

关 键 词：恩替卡韦 康莱特注射液 乙型肝炎病毒 感染 晚期肝癌 

分 类 号：R512.62[医药卫生—内科学]